Amoneta Diagnostics has been granted 5 Mio€ EU funding by the European Commission for its ADDIA project within the frame of Horizon-2020 PHC12 SME Instrument.
The company will develop and market a fast, reliable and non-invasive peripheral blood diagnostic kit for Alzheimer’s Disease (AD). ADDIA consortium, coordinated by Amoneta will validate the ADDIA in vitro diagnostic (IVD) test candidate via a multi-center Proof-of-Performance (PoP) clinical study in 800 subjects including 400 AD patients.
At the end of ADDIA project, a validated and CE-marked IVD biomarker test will be available for AD diagnosis application and for disease-modifying drug development (patient stratification and monitoring drug efficacy in clinical trials). For more information, please visit the project website: http://www.addia-project-h2020.eu/
Amoneta Diagnostics obtains an EU funding by the EuroTransBio (ETB) committee for its ADKIT project, which aims to develop a fast and simple peripheral blood diagnostic kit for Alzheimer’s disease. Amoneta Diagnostics is coordinator of the consortium, which regroups the German SME JPT Peptide Technologies, the Colmar Hospital and the CNRS from Strasbourg.